Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals (Glenmark), a research-led, global pharmaceutical company today announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.